Product; Progenitor Cell Therapy LLC is Retained to Develop and Manufacture AMR-001

Businesswire.com (Associated Press)
PharmaManufacturing.com.
07/06/2006

Amorcyte Inc (Amorcyte), a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, announced that it has signed an exclusive agreement for the development and manufacturing of Amorcyte's lead product, AMR-001, with Progenitor Cell Therapy, LLC (PCT), a leading full service cell therapy development and contract manufacturing company.

"The product development and manufacturing agreement with Progenitor Cell Therapy is a critical component of our corporate and product development plan," explains Dr. Thomas Moss, Amorcyte's Chief Medical Officer. "Our strategic relationship with PCT enables our development team to draw on PCT's unique and extensive investigative, regulatory and commercial experience in the applied cell therapy field."

"Leveraging PCT for development of AMR-001 will allow Amorcyte to reduce capital outlay. This will contribute to efficient conduct of the clinical trial for AMR-001, while enabling Amorcyte to pursue other potential related product development opportunities," said President of Progenitor Cell Therapy, Dr. Robert Preti.

AMR-001 is an autologous bone marrow-derived cell product being tested to determine if its infusion into the coronary (heart) artery after myocardial infarct can restore heart muscle function in tissue damaged by the heart attack.

About Amorcyte Inc

Amorcyte Inc is a therapeutics company pursuing cell-based therapies for cardiovascular diseases, reimbursable on a commercial scale for widespread clinical use. Amorcyte was incorporated in May 2005 and received FDA approval for its Phase I trial IND in September 2005.